Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome.?
This report aims to provide a comprehensive presentation of the global market for HIV Associated Lipodystrophy Syndrome Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Associated Lipodystrophy Syndrome Treatment. This report contains market size and forecasts of HIV Associated Lipodystrophy Syndrome Treatment in global, including the following market information:
Global HIV Associated Lipodystrophy Syndrome Treatment Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global HIV Associated Lipodystrophy Syndrome Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Specific Drug Treatment Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of HIV Associated Lipodystrophy Syndrome Treatment include Gilead Sciences, Amgen, Abbott, AstraZeneca, AbbVie, GlaxoSmithKline, Alfa Wassermann SPA, Theratechnologies and Bristol-Myers Squibb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the HIV Associated Lipodystrophy Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HIV Associated Lipodystrophy Syndrome Treatment Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, by Type, 2022 (%)
Specific Drug Treatment
Cosmetic Corrective Treatment
Global HIV Associated Lipodystrophy Syndrome Treatment Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital
Specialist Clinic
Others
Global HIV Associated Lipodystrophy Syndrome Treatment Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global HIV Associated Lipodystrophy Syndrome Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies HIV Associated Lipodystrophy Syndrome Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies HIV Associated Lipodystrophy Syndrome Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead Sciences
Amgen
Abbott
AstraZeneca
AbbVie
GlaxoSmithKline
Alfa Wassermann SPA
Theratechnologies
Bristol-Myers Squibb
Outline of Major Chapters:
Chapter 1: Introduces the definition of HIV Associated Lipodystrophy Syndrome Treatment, market overview.
Chapter 2: Global HIV Associated Lipodystrophy Syndrome Treatment market size in revenue.
Chapter 3: Detailed analysis of HIV Associated Lipodystrophy Syndrome Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HIV Associated Lipodystrophy Syndrome Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 HIV Associated Lipodystrophy Syndrome Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global HIV Associated Lipodystrophy Syndrome Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global HIV Associated Lipodystrophy Syndrome Treatment Overall Market Size
2.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size: 2022 VS 2030
2.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market
3.2 Top Global HIV Associated Lipodystrophy Syndrome Treatment Companies Ranked by Revenue
3.3 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Companies
3.4 Top 3 and Top 5 HIV Associated Lipodystrophy Syndrome Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies HIV Associated Lipodystrophy Syndrome Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market
3.6.1 List of Global Tier 1 HIV Associated Lipodystrophy Syndrome Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Markets, 2022 & 2030
4.1.2 Specific Drug Treatment
4.1.3 Cosmetic Corrective Treatment
4.2 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
4.2.1 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2023
4.2.2 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2024-2030
4.2.3 By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Specialist Clinic
5.1.4 Others
5.2 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
5.2.1 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2023
5.2.2 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2024-2030
5.2.3 By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2022 & 2030
6.2 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue & Forecasts
6.2.1 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2023
6.2.2 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2024-2030
6.2.3 By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030
6.3.2 US HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.3.3 Canada HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.3.4 Mexico HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030
6.4.2 Germany HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.3 France HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.4 U.K. HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.5 Italy HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.6 Russia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.7 Nordic Countries HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.4.8 Benelux HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030
6.5.2 China HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.5.3 Japan HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.5.4 South Korea HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.5.5 Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.5.6 India HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030
6.6.2 Brazil HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.6.3 Argentina HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030
6.7.2 Turkey HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.7.3 Israel HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.7.4 Saudi Arabia HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
6.7.5 UAE HIV Associated Lipodystrophy Syndrome Treatment Market Size, 2018-2030
7 HIV Associated Lipodystrophy Syndrome Treatment Companies Profiles
7.1 Gilead Sciences
7.1.1 Gilead Sciences Company Summary
7.1.2 Gilead Sciences Business Overview
7.1.3 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.1.4 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.1.5 Gilead Sciences Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.2.4 Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 Abbott
7.3.1 Abbott Company Summary
7.3.2 Abbott Business Overview
7.3.3 Abbott HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.3.4 Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.3.5 Abbott Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.4.4 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 AbbVie
7.5.1 AbbVie Company Summary
7.5.2 AbbVie Business Overview
7.5.3 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.5.4 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.5.5 AbbVie Key News & Latest Developments
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Company Summary
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.6.4 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.6.5 GlaxoSmithKline Key News & Latest Developments
7.7 Alfa Wassermann SPA
7.7.1 Alfa Wassermann SPA Company Summary
7.7.2 Alfa Wassermann SPA Business Overview
7.7.3 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.7.4 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.7.5 Alfa Wassermann SPA Key News & Latest Developments
7.8 Theratechnologies
7.8.1 Theratechnologies Company Summary
7.8.2 Theratechnologies Business Overview
7.8.3 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.8.4 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.8.5 Theratechnologies Key News & Latest Developments
7.9 Bristol-Myers Squibb
7.9.1 Bristol-Myers Squibb Company Summary
7.9.2 Bristol-Myers Squibb Business Overview
7.9.3 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Major Product Offerings
7.9.4 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global Market (2018-2023)
7.9.5 Bristol-Myers Squibb Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. HIV Associated Lipodystrophy Syndrome Treatment Market Opportunities & Trends in Global Market
Table 2. HIV Associated Lipodystrophy Syndrome Treatment Market Drivers in Global Market
Table 3. HIV Associated Lipodystrophy Syndrome Treatment Market Restraints in Global Market
Table 4. Key Players of HIV Associated Lipodystrophy Syndrome Treatment in Global Market
Table 5. Top HIV Associated Lipodystrophy Syndrome Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies HIV Associated Lipodystrophy Syndrome Treatment Product Type
Table 9. List of Global Tier 1 HIV Associated Lipodystrophy Syndrome Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 HIV Associated Lipodystrophy Syndrome Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - HIV Associated Lipodystrophy Syndrome Treatment Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2024-2030
Table 30. Gilead Sciences Company Summary
Table 31. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 32. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Gilead Sciences Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 36. Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Amgen Key News & Latest Developments
Table 38. Abbott Company Summary
Table 39. Abbott HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 40. Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Abbott Key News & Latest Developments
Table 42. AstraZeneca Company Summary
Table 43. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 44. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. AstraZeneca Key News & Latest Developments
Table 46. AbbVie Company Summary
Table 47. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 48. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. AbbVie Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 52. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Alfa Wassermann SPA Company Summary
Table 55. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 56. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Alfa Wassermann SPA Key News & Latest Developments
Table 58. Theratechnologies Company Summary
Table 59. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 60. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Theratechnologies Key News & Latest Developments
Table 62. Bristol-Myers Squibb Company Summary
Table 63. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Product Offerings
Table 64. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Bristol-Myers Squibb Key News & Latest Developments
List of Figures
Figure 1. HIV Associated Lipodystrophy Syndrome Treatment Segment by Type in 2022
Figure 2. HIV Associated Lipodystrophy Syndrome Treatment Segment by Application in 2022
Figure 3. Global HIV Associated Lipodystrophy Syndrome Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by HIV Associated Lipodystrophy Syndrome Treatment Revenue in 2022
Figure 8. By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 9. By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 10. By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 12. By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 14. By Region - Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 15. By Country - North America HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 16. US HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 17. Canada HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 20. Germany HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 21. France HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 23. Italy HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 24. Russia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 28. China HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 29. Japan HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 32. India HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 34. Brazil HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share, 2018-2030
Figure 37. Turkey HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 38. Israel HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 40. UAE HIV Associated Lipodystrophy Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 41. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
